How Can Innovation and Opportunity Guide a Career in Nursing Research?
“Nursing is at the forefront of symptom management, and nurse-designed interventions lead the way,” Gwen Wyatt, RN, PhD, FAAN, FAPOS, recipient of the 2020 ONS Distinguished Nurse Researcher Award, said in a session at the inaugural ONS BridgeTM virtual conference in September 2020. She shared lessons from her career journey and told nurses that ONS can help them get their ideas “off the drawing board.”
FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma
On January 14, 2021, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori®) for pediatric patients aged one year or older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK) positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Genomics Provides Insight on Exceptionally Responding Patients
Patients with cancer who experience unexpected and long-lasting treatment outcomes are considered exceptional responders, but researchers and clinicians had no insight as to why the patients did so well with treatment. Results of a new study now show that genomic characterizations of cancer can uncover genetic alterations that may contribute to the phenomenon, researchers reported in Cancer Cell.
How COVID-19 May Increase Access to and Reduce Disparities in Cancer Clinical Trials
To improve clinical trial availability, effectiveness, and diversity in the era of the COVID-19 coronavirus, National Cancer Institute (NCI)-funded clinical trials should adjust their design to increase use of telemedicine and remote informed consent, among other strategies, several NCI department leaders wrote in a commentary in the Journal of the National Cancer Institute.
NCI Links Persistent Poverty to Increased Cancer Mortality
Where a person lives has the biggest impact on their healthcare accessibility and affordability. In a new study, researchers from the National Cancer Institute (NCI) found strong correlation between persistent poverty and cancer mortality in the United States, NCI’s Division of Cancer Control and Population Sciences (DCCPS) reported in Cancer Epidemiology, Biomarkers, and Prevention.
FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
On November 25, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza®) in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who demonstrate a partial response, minor response, or stable disease to prior therapy.
What the Evidence Says for Cannabis in Cancer Care
An annual flowering herb native to East Asia, Cannabis sativa is cultivated around the world. It is used in traditional medicine as an analgesic, hypnotic, hallucinogenic, sedative, and anti-inflammatory. Preparations derived from its flowers, leaves, and hashish made from its resinous extract are taken orally, by smoking, or by vaporizing. Cannabis teas, tinctures, ointments, and oil-based extracts that can be mixed into food products are also popular.
Blocking Fatty Acid Storage May Induce Glioblastoma Apoptosis
Turning off an enzyme that glioblastoma cells use to store the fatty acids they feed on as energy for rapid cell division may offer a new treatment option for the deadly cancer, researchers reported in Cell Metabolism.
Medications That Affect Microbiome May Influence Checkpoint Inhibitory Response
Common classes of non-cancer medications that affect a patient’s microbiome are associated with increased or decreased survival with immune checkpoint inhibitor drugs, researchers reported in study findings published in BMC Cancer.
We Must Work to Achieve Health Equity in Cancer Research
The National Institutes of Health Revitalization Act of 1993 mandated appropriate inclusion of minorities in all NIH-funded research. Yet more than 20 years later, vast disparities still exist in cancer research, researchers reported in a session for the inaugural ONS Bridge™ virtual conference.
Innovation and Opportunity Lead to a Distinguished Career in Nursing Research
“Nursing is at the forefront of symptom management, and nurse-designed interventions lead the way,” Gwen Wyatt, RN, PhD, FAAN, FAPOS, recipient of the 2020 ONS Distinguished Nurse Researcher Award, said in a session at the inaugural ONS Bridge™ virtual conference. She shared lessons from her career journey and told nurses that ONS can help them get their ideas “off the drawing board.”
MicroRNA May Be Key Factor in High-Grade Ovarian Cancer Development
The miR-181a microRNA may turn off two genes and lead to the development of high-grade serous ovarian cancer, researchers reported in Nature Communications. The finding is significant because not much is known about how ovarian cancer develops and it’s difficult to detect in its earlier stages.
NCI-Partnered Global Research Initiative Confronts Tough Barriers to Cancer Progress
Since its inception in 2015, Cancer Research UK’s (CRUK) Cancer Grand Challenges initiative has led an international research effort to address the toughest barriers to progress in oncology, investing more than $130 million into seven international, multidisciplinary teams—total of 73 researcher groups in nine countries.
Acknowledge and End Unequal Representation in Cancer Research and Improve Access to Care
Research influences care along every inch of the cancer continuum, from prevention to survivorship, enabling healthcare professionals and patients to share decisions that result in the most current and tailored care strategies. It’s a powerful tool that sets the groundwork for providing optimal health outcomes. However, we must work to eliminate unequal representation.
FDA Program Shares PROs From Cancer Clinical Trials
Cancer clinical trials often collect patient-reported outcome (PRO) data, but the information is generally used just for that trial. Recognizing the value of making it available to healthcare providers everywhere, in July 2020, the U.S. Food and Drug Administration (FDA) launched Project Patient Voice, a pilot program designed to share clinical trial PROs on an easy-to-access website.
Insulin Resistance May Explain Racial Disparity in Breast Cancer
Black women with breast cancer typically have a worse prognosis than white women, and the results of a new study suggest that insulin resistance may be a factor in the disparity. Findings from the study were reported in Breast Cancer Research.
Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time
More than 96% of participants in prostate cancer clinical trials are non-Hispanic white men even though non-Hispanic black men represent 22% of prostate cancer diagnoses, researchers reported in Cancer Epidemiology, Biomarkers, and Prevention. Even more critical, enrollment rates of black or African American men have been declining since 1995.
NIH Appoints New NINR Director
Beginning this fall, the National Institute of Nursing Research (NINR) will have a nurse in a permanent position to lead the agency. On July 1, 2020, the National Institutes of Health (NIH) named Shannon N. Zenk, PhD, MPH, RN, FAAN, as its new director. Zenk is currently a nursing collegiate professor in the Department of Population Health Nursing Science at the University of Illinois at Chicago College of Nursing, and a fellow at the UIC Institute for Health Research and Policy.
Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment
A new class of drugs, antibody-drug conjugates (ADCs), combines the specificity of targeted therapy with the cytotoxicity of chemotherapy for a powerhouse effect against certain types of cancer variants. Here’s what you need to know about this novel treatment modality.
Cancer Consortium Report Reveals High Mortality Rates in Patients With COVID-19 and Cancer
Patients with cancer who contracted the COVID-19 coronavirus had high rates of 30-day all-cause mortality that was associated with general risk factors and risk factors unique to cancer, according to findings from one of the first data registry reports of patients with the dual diagnoses. The results were published in Lancet.
Exercise Before ADT Treatment Reduces Rate of Side Effects
Beginning a supervised exercise program before the start of androgen deprivation therapy (ADT) for prostate cancer reduced the incidence of treatment-related side effects, researchers reported in a study published in BJU International.
NIH Partners With Johnson and Johnson to Combat COVID-19
Long hailed as the “crown jewel” of the U.S. government’s biomedical research division, the National Institutes of Health (NIH) is partnering with Johnson and Johnson for a coordinated, team-based effort to find measures with meaningful impact on the COVID-19 coronavirus pandemic.
Investigational Maintenance Therapy Extends Survival in AML
A new drug is extending both remission and survival in adults with acute myeloid leukemia (AML), according to findings reported at the American Society of Hematology annual meeting in December 2019. The study was funded by Celgene, the drug’s manufacturer.
Research Is Needed to Better Understand Combination Immunotherapy Side Effects
Combination immunotherapy treatments are revolutionizing the way cancer care is delivered. As an ongoing evolution of care, nurses are administering different treatment modalities on a regular basis. Treatments include using multiple immunotherapy drugs in tandem, combining chemotherapy with immunotherapy, using targeted therapies with immunotherapy, and even involving radiation with immunotherapy. The move toward multiple-drug modalities will continue to change nursing practice, and nurses must have a basis of knowledge and evidence from which to work.
NIH Announces Research Strategy for COVID-19
From international guidelines to economic stimulus and legislative support, the COVID-19 coronavirus pandemic is now global leaders’ top priority. Leading the research efforts is the National Institutes for Health’s (NIH) National Institute of Allergy and Infectious Disease (NIAID). As NIAID’s director for more than 30 years, Anthony Fauci, MD is one of the few, regular faces associated with COVID-19 in the United States. On April 23, 2020, the agency announced that it will spearhead a strategic plan to research a vaccine for COVID-19.
NCI Cancer Research Persists Despite COVID-19 Limitations
Most of the global biomedical research community, especially those at the National Institutes of Health (NIH), is consumed with the COVID-19 coronavirus pandemic. Because the U.S. federal government is under strict orders to limit its operations to only essential personnel, many of the 27 NIH institutes and centers are redirecting their efforts toward COVID-19 topics. However, the National Cancer Institute (NCI) is continuing its cancer research in certain priority areas.
Latinas’ Breast Cancer Genetic Disparities Require More Focused Counseling and Testing
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in Latina women. Compared to all patients with breast cancer, Latinas are the second most common ethnic group to carry BRCA1 deleterious mutations, after Ashkenazi Jewish women. However, Latinas are less likely to receive genetic counseling education, referrals, and testing services and have the least awareness of genetic testing compared to non-Hispanic whites and other minority populations. Research indicates that despite their low awareness, Latinas have high interest in participating in genetic counseling and testing.
Pembrolizumab Is More Cost Effective Than Atezolizumab for NSCLC
Adding atezolizumab to treatment with bevacizumab, carboplatin, and paclitaxel as first-line therapy for metastatic, nonsquamous non-small cell lung cancer (NSCLC) is associated with survival benefit—but it comes at a cost, researchers said in study results published in JAMA Network Open. In comparison, pembrolizumab offers a more cost-effective survival benefit.
The Case of the Candy-Coated (Mis)Conception
P.G. is a 54-year-old woman who presents to the infusion center to receive her second cycle of chemotherapy for breast cancer. As her oncology nurse, you check the chemotherapy orders and patient history and are concerned to see that her weight has dropped by 10% from baseline, necessitating a change in dosing.
Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips
The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.
Personalized Combination Therapies Yield Better Cancer Outcomes
In a perpetual search to refine research and scientific advancements in the pursuit of fighting cancer, the National Institutes of Health (NIH) is investing in research that will help practitioners further understand how treatments and combinations of treatments can benefit patients. Through a focus on precision oncology, researchers are examining which combinations of therapies would work best for each individual patient based on a number of factors, including genetics and genomics.
Congress Tackles Youth Smoking; Pelosi Drug Pricing; Biden's Cancer Commitment
Healthcare advocates assembled in the U.S. Congress to hear from panelists about the national epidemic of youth smoking. From those conversations, a common theme emerged: many believe that the rise in youth vaping and smoking is directly related to marketing and sales tactics by large tobacco manufacturers.
FDA Oncology Center of Excellence Establishes a Commitment to Patients
The U.S. Food and Drug Administration’s (FDA’s) mission is primarily to protect the American public by regulating the sale and development of consumer items like cosmetics, food, tobacco products, medication, and much more. However, a lesser known arm is FDA’s Oncology Center of Excellence, established to further prevention, detection, patient-centered research, and cancer-specific education.
Trump Promises $500 Million Increase to Pediatric Cancer Research
Pediatric cancers have more than an 80% overall cure rate, and that, at first glance, seems like something to celebrate. However, in terms of lives lost to different pediatric cancers, the American Cancer Society estimated that more than 1,100 children under the age of 15 will die from their disease in 2019—roughly one in five children diagnosed. Although survival rates are improving in cancers like acute lymphocytic leukemia and Hodgkin lymphoma, other childhood cancer types haven’t seen increased survival since the early 2000s.
Experience the Power of Patient-Centered Research Through PCORI
How often have you gone to the mailbox, pulled out your latest issue of the or , and excitedly read about some innovative study with game-changing outcomes that’ll revolutionize the delivery of health care—only to find that it never moves off the pages of the journal? What does it take to move research from the proverbial bench to the community? That was the focus of the Fourth Annual Meeting of the Patient Centered Outcomes Research Institute (PCORI), “ ” held from October 31–November 2, 2018, in Washington DC.
President’s Cancer Panel Calls for Renewed Commitment to Vaccinate for HPV
For years, the human papillomavirus vaccination (HPV) has been recommended to young adult patients to help prevent certain forms of cancer. In a November 2018 report, the President’s Cancer Panel recommended to further the United States’ goal to prevent cancer associated with HPV.
Cancer Moonshot Moves to Research Phase
Still a popular program throughout the government, the , encourage collaboration in finding treatments and cures, and to improve data sharing to make a decade’s progress in half the time. Through NIH’s Moonshot Blue Ribbon Panel and the 2016 passage of the 21st Century Cures Act—allocating $1.8 billion over seven years for Moonshot—the initiative is moving out of planning and into the research phase.
Former President Bush’s Legacy Holds Strong Commitment to Advancing Cancer Care
As a staunch advocate for the advancement of cancer treatments, research, and patient care, President George H.W. Bush left an enduring legacy through contributions to the field of oncology and health care in the wake of his death on November 30, 2018. His continued support of healthcare professionals—including oncology nurses—spoke to his administration’s focus before, during, and after his tenure in Washington, DC.
Advocacy Community Supports NCI Fiscal Year 2020 Proposal
A billion dollars was once an astronomical amount of money to spend on one federal agency. But since the 1950s when Senator Dirksen (R-IL) was a leading voice for fiscal conservatives, the federal government’s budget has ballooned, with both political parties equally responsible for increases. During this time, great achievements have been made, and much of it in biomedical research at the National Institutes of Health (NIH), as what former Senator Arlen Specter (R-PA) often referred to as the crown jewel of the federal government.
Medicare Cracks Down on Opioid Prescriptions, Abuse; Health Care Tops Poll of American Worries; Leading Chemotherapy Researcher, Physician Dies at 92
An estimated 14.4 million Medicare recipients were prescribed some form of opioid treatment in 2016, paid for by their Medicare benefits. In an attempt to help curb the national opioid epidemic, officials from the Center for Medicare and Medicaid Services (CMS) announced that Medicare would no longer pay for long-term, high-dose prescription pain medication. Unsurprisingly, the plan received flak from patient and provider advocacy groups alike. Opponents to the CMS announcement decried the efforts, citing barriers to crucial medications needed for patients in chronic or severe pain—including those with cancer.
Key Funding Increases for Cancer Research, Nursing, Public Health; Patients, Providers, or Politicians: Whose Choices Matter Most?; FDA Targets Flavored Tobacco Products
Racing against the clock to ensure the government stayed funded through September 2018, President Trump signed the Consolidation Appropriations Act, a $1.3 trillion spending bill that includes funding for a number of key nursing and public health initiatives. The bill, which had made its way through the House of Representatives and the Senate last week, also contains new clarifying language for the Dickey Amendment, ending a 22-year ban on government-funded gun violence research. ONS joined the Nursing Community Coalition—led in part by the efforts of the American Nurses Association—to support evidence-based inquiry into gun violence and its potential impacts on public health.
FDA Approves Brentuximab Vedotin for Previously Untreated Stage III, IV Classical Hodgkin Lymphoma
On March 20, 2018, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.